RNAi therapeutics is now started taking momentum after successful clinical trials for different siRNA-based therapies, primarily for neural disorders and cancers. Their specificities in terms of post-transcriptional gene silencing have already been well established and many small and big players are engaged in designing and patenting novel RNAi sequences. Designing specific sequences for specific disease or disorders does not complete the invention, but it does also require maneuvering specific delivery agents for targeted delivery.Lipid-based delivery agents are primarily used for delivering different RNAi molecules, but other chemical agents such as peptides, DAEA-dextran etc. and biological agents such as viral particles have also been tried and tested.
Globally, North America dominates the nucleic acid aptamer market, due to its favorable policies for clinical trials, which is driving the market growth. It is estimated that nucleic acid aptamer market will reach nearly $5.4 billion by 2020, with a compound annual growth rate (CAGR) of 73.5% from 2015 to 2020.
Based on the drug delivery and therapeutics applications the RNAi market is segmented. The drug delivery of RNAi is further divided into nucleic acid drug delivery technology, aptamer drug delivery technology, nanoparticle drug delivery technology, and pulmonary drug delivery technology. Therapeutic application market further segmented into oncology, cardiology, ophthalmology, neurology and metabolic disorders.Nanoparticle-based drug delivery is largest sub-segment, however, aptamer drug delivery technology is the fastest growing segment.
More than fifteen hundred clinical trials for nucleic acid delivery are ongoing worldwide. Approximately 55% are in the primary clinical development stage and 4% in phase III trials which shows that nucleic acid delivery market is growing rapidly.
The nucleic acid used for therapeutics
Geographically IP filing activity
In Asia, less filing has been observed in this domain in 2017. Japan (XX) is the most active jurisdiction, followed by China (XX), Korea (XX) and India (XX).
- Overview of Nucleic acid delivery, including unique challenges, categories of RNA interference (RNAi) used for therapy, specific carriers and technique of delivering a nucleic acid, role of delivery systems in therapy and disease covered.
- Different nucleic acids used for therapy such as siRNA, miRNA, mRNA, shRNA, gRNA. Studies on current academic research and industry trend, geographical distribution of therapeutics, key diseases targeted for treatment, clinical trials for different diseases, different delivery agents and techniques to deliver nucleic acid utilized.
Key topics covered includes:
- Nucleic acid delivery market segmentation by geography, application, end user & product
- Industry movement partnerships, agreements, collaborations, expansions, acquisitions, and product & service launches in the market
- Strategic SWOT & PEST analysis, nucleic acid delivery market characterization i.e. development and determinants
- Analysis of the current and future market drift in the global Nucleic acid delivery market. Perspicacious review of the key industry opportunity, restraints and, challenges
- Market assessment of nucleic acid delivery in therapeutics
Key questions answered in the report
- What are different types of nucleic acid used as therapeutic agents?
- What are different nucleic acid delivery agents and delivery techniques used?
- What are the key challenges associated with the current delivery systems?
- Will the pipeline carriers under development and clinical trials overcome these challenges and problems associated with current delivery systems?
- What is the technology trend prevalent in the usage of RNAi as therapeutic agent?
- Who are the key companies & universities actively working on the usage of RNAi as a therapeutic agent?
- What is the key disease targeted i.e. animal and plant diseases?
- What are the different plant diseases covered and future prospect of RNAi as a biosafe eco-friendly tool for plant pathologists?
- What are the technological innovations pursued by these companies & universities?
- What are the opportunities and restraints for RNAi delivery technologies in therapeutics?
- What are the technology forecasts & core technologies, ongoing prosecutions, statistical analytics, citations & classifications etc. for RNAi as a therapeutic agent?
- What are the market determinants and market trends with respect to different geographic regions?
- What are the major industrial movements in terms of partnerships, agreements, collaborations, expansions, acquisitions, and product & service launches in the market?
### IEBS offers tailored information as per client needs viz. additional company profiling (up to 10), partner identification, regions which are untapped, key strategies employed by the target companies for their sustenance in the studied field etc.
1. Technology Overview
1.2. Executive Summary
1.3. Technical Segmentation
2. Technology Insights
2.1. The nucleic acid used for therapeutics
22.214.171.124. SiRNA – Current academic research
126.96.36.199. SiRNA – The Current industrial trend
188.8.131.52. SiRNA – Geographical distribution for siRNA therapeutics
184.108.40.206. SiRNA – Key diseases targeted using siRNA therapeutics
220.127.116.11. siRNA – Delivery agents for SiRNA
18.104.22.168. miRNA – Current academic research
22.214.171.124. miRNA – The Current industrial trend
126.96.36.199. miRNA – Geographical distribution for miRNA Therapeutics
188.8.131.52. miRNA – Key diseases targeted using miRNA Therapeutics
184.108.40.206. miRNA – Delivery agents for miRNA
220.127.116.11. mRNA – Current academic research
18.104.22.168. mRNA – The Current industrial trend
22.214.171.124. mRNA – Geographical distribution for mRNA therapeutics
126.96.36.199. mRNA – Key diseases targeted using mRNA therapeutics
188.8.131.52. mRNA – Delivery agents for mRNA
184.108.40.206. shRNA – Current academic research
220.127.116.11. shRNA – The Current industrial trend
18.104.22.168. shRNA – Geographical distribution for shRNA therapeutics
22.214.171.124. shRNA – Key diseases targeted using shRNA therapeutics
126.96.36.199. shRNA – Delivery agents for shRNA
188.8.131.52. gRNA – Current academic research
184.108.40.206. gRNA – The Current industrial trend
220.127.116.11. gRNA – Geographical distribution for gRNA therapeutics
18.104.22.168. gRNA – Key diseases targeted using gRNA therapeutics
22.214.171.124. gRNA – Delivery agents for gRNA
2.1.6. Key players distribution w.r.t type of Nucleic acid
2.1.7. Nucleic acid delivery system: from bench to Clinical trials for different diseases.
2.1.8. Sentiment analysis: Nucleic acid therapy
2.2. Nucleic acid delivery agents
2.2.1. Liposomes as a delivery agent
126.96.36.199. Liposomes – Advantages/Disadvantages
188.8.131.52. Liposomes – Key industrial players
184.108.40.206. Liposomes – Key academic players
220.127.116.11. Liposomes – Important innovations
18.104.22.168. Liposomal NA delivery – Diseases targeted
2.2.2. Lipid nanoparticles as a delivery agent
22.214.171.124. Lipid nanoparticles – Advantages/Disadvantages
126.96.36.199. Lipid nanoparticles – Key industrial players
188.8.131.52. Lipid nanoparticles – Key academic players
184.108.40.206. Lipid nanoparticles – Important innovations
220.127.116.11. Lipid nanoparticles NA delivery – Diseases targeted
2.2.3. Lipofectamine as a delivery agent
18.104.22.168. Lipofectamine – Advantages/Disadvantages
22.214.171.124. Lipofectamine – Key industrial players
126.96.36.199. Lipofectamine – Key academic players
188.8.131.52. Lipofectamine – Important innovations
184.108.40.206. Lipofectamine NA delivery – Diseases targeted
2.2.4. Nanoparticles as a delivery agent
220.127.116.11. Nanoparticles – Advantages/Disadvantages
18.104.22.168. Nanoparticles – Key industrial players
22.214.171.124. Nanoparticles – Key academic players
126.96.36.199. Nanoparticles – Important innovation
188.8.131.52. Nanoparticles NA delivery – Diseases targeted
2.2.5. Protein/Peptides as a delivery agent
184.108.40.206. Protein/Peptides – Advantages/Disadvantages
220.127.116.11. Key industrial players
18.104.22.168. Key academic players
22.214.171.124. Protein/Peptides – Important innovation
126.96.36.199. Protein/Peptides based NA delivery – Diseases targeted
2.2.6.Other nucleic acid delivery agents
188.8.131.52. Lipoplex as a delivery agent
184.108.40.206. Lipidoid as a delivery agent
220.127.116.11. Plant virus capsids as a delivery agent
18.104.22.168. HPV particle as delivery agent
22.214.171.124. Nanoparticle mimics as a delivery agent
126.96.36.199. Dendrimers as a delivery agent
2.2.7. Key players focusing on different nucleic acid delivery agents
2.2.9.Recent advances in nucleic acid delivery agents (viz. cholesterol-based lipidused for mRNA delivery)
2.3. Nucleic acid delivery techniques
2.3.1. Electroporation for Nucleic acid delivery
188.8.131.52. Electroporation – Advantages/Disadvantages
184.108.40.206. Key industrial players
220.127.116.11. Key academic players
18.104.22.168. Electroporation – Important innovation
22.214.171.124. Electroporation-based NA delivery – Diseases targeted
2.3.2. Microinjection for Nucleic acid delivery
126.96.36.199. Microinjection – Advantages/Disadvantages
188.8.131.52. Key industrial players
184.108.40.206. Key academic players
220.127.116.11. Microinjection – Important innovation
18.104.22.168. Microinjection based NA delivery – Diseases targeted
2.3.3.Transfection for Nucleic acid delivery
22.214.171.124. Transfection – Advantages/Disadvantages
126.96.36.199. Key industrial players
188.8.131.52. Key academic players
184.108.40.206. Transfection – Important innovation
220.127.116.11. Transfection based NA delivery – Diseases targeted
2.3.4.DAEA-dextran mediated Nucleic acid delivery
18.104.22.168. DAEA-dextran mediate- Advantages/Disadvantages
22.214.171.124. Key industrial players
126.96.36.199. Key academic players
188.8.131.52. DAEA-dextran mediated NA delivery – Important innovation
184.108.40.206. DAEA-dextran mediated NA delivery – Diseases targeted
2.3.5. Key players focusing on different nucleic acid delivery techniques
2.4. Disease-targeted for treatment
2.4.1. Cancer treatment using NA delivery
2.4.2. Plant rot treatment using NA delivery
2.4.3. Leaf blight treatment using NA delivery
2.4.4. Bone disorder treatment using NA delivery
2.4.5. Eye disorder treatment using NA delivery
2.4.6. Arthritis treatment using NA delivery
2.4.7. Diabetes treatment using NA delivery
2.4.8. Metabolic disorder treatment using NA delivery
2.4.9. Cardiovascular disease treatment using NA delivery
2.4.9. Immune disease treatment using NA delivery
3. Geographical distribution
3.1. Geographically IP filing activity
3.2. IP filing in Asia
3.3. IP filing in rest of world
4. Partnership / Collaboration / Licensing
4.1. Partnership / Collaboration / Licensing objective
4.2. Information of associated companies
4.1. Collaboration between companies
4.2. Collaboration between company and universities
4.1. Licensing activity
4.2. Acquisition in the technology domain
5. Nucleic acid delivery – Market overview
5.1. Market Segmentation based on Nucleic acid therapeutics
5.2. Market Segmentation based on Nucleic acid delivery agents
5.1. Market Segmentation based on Nucleic acid delivery techniques
6. Nucleic acid delivery: Market Determinants
7. Nucleic acid delivery: Opportunity Vs. Restraints
8. Nucleic acid delivery: Strategic Analysis SWOT & PEST
9. Nucleic acid delivery: Market Development
9. Nucleic acid delivery: Recent advancements and future trend